Egetis Therapeutics
3,685
SEK
-1,6 %
Mindre end 1K følgere
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
-1,6%
-24,25%
-47,36%
-44,08%
-19,72%
-44,5%
-24,22%
-24,39%
-73,37%
Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Egetis Therapeutics was founded in 2005 and is headquartered in Stockholm, Sweden.
Læs mereMarkedsværdi
1,43 mia. SEK
Aktieomsætning
1,66 mio. SEK
Omsætning
46,1 mio.
EBIT %
-714,53 %
P/E
-
Udbytteafkast, %
-
Finanskalender
30.4
2025
Delårsrapport Q1'25
6.5
2025
Generalforsamling '25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Egetis Therapeutics, Audiocast with teleconference, Q4'24
Year-End Report January-December 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® (tiratricol) on March 4, 2025
Invitation to Presentation of Egetis’ Fourth Quarter and Year-End 2024 Report on February 26, 2025
Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day
European Commission approves Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency
Change in the number of shares and votes in Egetis Therapeutics
Egetis highlights the positive CHMP opinion for Emcitate®, recent major milestones, and gives a corporate update at Investor Day in Stockholm today
Issuance and repurchase of class C shares for incentive programs
Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency
Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate®)
Save the Date: Egetis to host Investor Day on December 18, 2024
Redeye: Egetis Q3 2024: Financing secured, progress with Emcitate in US and EU
